Catalyst Pharmaceuticals Inc (CPRX)vsInsmed Inc (INSM)
CPRX
Catalyst Pharmaceuticals Inc
$23.80
+3.16%
HEALTHCARE · Cap: $2.84B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 3% more annual revenue ($606.42M vs $588.99M). CPRX leads profitability with a 36.4% profit margin vs -2.1%. CPRX earns a higher WallStSmart Score of 59/100 (C).
CPRX
Buy59
out of 100
Grade: C
INSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-109.5%
Fair Value
$11.42
Current Price
$23.80
$12.38 premium
Intrinsic value data unavailable for INSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 40.5%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
No standout strengths identified
Areas to Watch
Weak financial health signals
Earnings declined 6.4%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CPRX
The strongest argument for CPRX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 36.4% and operating margin at 40.5%.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CPRX
The primary concerns for CPRX are Piotroski F-Score, EPS Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CPRX profiles as a mature stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
CPRX is growing revenue faster at 7.6% — sustainability is the question.
CPRX generates stronger free cash flow (45M), providing more financial flexibility.
Bottom Line
CPRX scores higher overall (59/100 vs 39/100), backed by strong 36.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Catalyst Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?